The amino acid Asn136 in HIV-1 reverse transcriptase (RT) maintains efficient association of both RT subunits and enables the rational design of novel RT inhibitors

Molecular Pharmacology

Volumn 68, Issue 1, 2005, Pages 49-60

  Balzarini, Jan ^a   Auwerx, Joeri ^a   Rodríguez Barrios, Fátima ^b   Chedad, Allel ^c   Farkas, Viktor ^d   Ceccherini Silberstein, Francesca ^e   García Aparicio, Carlos ^f   Velázquez, Sonsoles ^f   De Clercq, Erik ^a   Perno, Carlo Federico ^e   Camarasa, María José ^f   Gago, Federico ^b  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b UNIVERSITY OF ALCALÁ   (Spain)

^c UNIVERSITY OF LEUVEN   (Belgium)

^d EÖTVÖS LORÁND UNIVERSITY   (Hungary)

^e UNIVERSITY OF ROME TOR VERGATA   (Italy)

^f INSTITUTO DE QUÍMICA MÉDICA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ASPARTIC ACID; DELAVIRDINE; DIMER; EFAVIRENZ; GW 420867; HISTONE; MONOMER; MUTANT PROTEIN; NEVIRAPINE; PEPTIDE; PROTEIN 51; PROTEIN 61; PROTEIN SUBUNIT; QUINOXALINE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; UNCLASSIFIED DRUG; UREA; VIRUS PROTEIN;

ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENATURATION; DIMERIZATION; DRUG SPECIFICITY; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME SUBUNIT; ESCHERICHIA COLI; GENETIC CONSERVATION; LIPOPHILICITY; MOLECULAR STABILITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN STRUCTURE; SITE DIRECTED MUTAGENESIS; WILD TYPE;

ASPARAGINE; CATALYSIS; DNA-DIRECTED DNA POLYMERASE; DRUG DESIGN; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MUTATION; PROTEIN STRUCTURE, SECONDARY; PROTEIN SUBUNITS; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 22444443468     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.105.012435     Document Type: Article

References (38)

1. Arion D, Fletcher RS, Borkow G, Camarasa M-J, Balzarini J, Dmitrienko GI, and Parniak MA (1996) Differences in the inhibition of human immunodeficiency virus type 1 reverse transcriptase DNA polymerase activity by analogs of nevirapine and [2′,5′-bis-O-(tert-butyldimethylsilyl)-3′- spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide] (TSAO). Mol Pharmacol 50:1057-1064.
2. Auwerx J, North TW, Preston BD, Klarmann GJ, De Clercq E, and Balzarini J (2002) Chimeric human immunodeficiency virus type 1 and feline immunodeficiency virus reverse transcriptases: role of the subunits in resistance/sensitivity to nonnucleoside reverse transcriptase inhibitors. Mol Pharmacol 61:400-406.
3. Baillon JG, Nashed N, Kumar A, Wilson SH, and Jerina DM (1991) A leucine zipper-like motif may mediate HIV reverse transcriptase subunit binding. New Biol 3:1015-1019.
4. Balzarini J (1999) Suppression of resistance to drugs targeted to human immunodeficiency virus reverse transcriptase by combination therapy. Biochem Pharmacol 58:1-27.
5. Balzarini J, Karlsson A, Vandamme A-M, Pérez-Pérez MJ, Zhang H, Vrang L, Öberg B, Backbro K, Unge T, San-Félix A, et al. (1993) Human immunodeficiency virus type 1 (HIV-1) strains selected for resistance against the HIV-specific [2′,5′-bis-O-(tert- butyldimethylsilyl)-3′-spiro-5″-(4″-amino-1″, 2″-oxathiole-2″,2″-dioxide)]-β-D-pentofuranosyl (TSAO) nucleoside analogues retain sensitivity to HIV-1-specific nonnucleoside inhibitors. Proc Natl Acad Sci USA 90:6952-6956.
6. Balzarini J, Kleim JP, Riess G, Camarasa M-J, De Clercq E, and Karlsson A (1994) Sensitivity of (138 Gly→Lys) mutated human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) to HIV-1-specific RT inhibitors. Biochem Biophys Res Commun 201:1305-1312.
7. Becerra SP, Kumar A, Lewis MS, Widen SG, Abbotts J, Karawya EM, Hughes SH, Shiloach J, and Wilson SH (1991a) Structure/function studies of HIV-11 reverse transcriptase: dimerization-defective mutant L289K. Biochemistry 30:11708-11719.
8. Becerra SP, Kumar A, Lewis MS, Widen SG, Abbotts J, Karawya EM, Hughes SH, Shiloach J, Wilson SH, and Lewis MS (1991b) Protein-protein interactions of HIV-1 reverse transcriptase: implications of central and C-terminal regions in subunit binding. Biochemistry 30:11707-11719.
9. Böhm G, Muhr R, and Jaenicke R (1992) Quantitative analysis of protein far-UV circular dichroism spectra by neural networks. Protein Eng 5:191-195.
10. Boyer PL, Ding J, Arnold E, and Hughes SH (1994) Subunit specificity of mutations that confer resistance to nonnucleoside inhibitors in human immunodeficiency virus type 1 reverse transcriptase. Antimicrob Agents Chemother 38:1909-1914.
11. Buckheit JRW, Fliakas-Bolz V, Decker WD, Roberson JL, Stup TL, Pyle CA, White EL, McMahon JB, Currens MJ, Boyd MR, et al. (1995) Comparative anti-HIV evaluation of diverse HIV-1-specific reverse transcriptase inhibitor-resistant virus isolates demonstrates the existence of distinct phenotypic subgroups. Antiviral Res 26:117-132.
12. Camarasa M-J, San-Félix A, Velázquez S, Pérez-Pérez M-J, Gago F, and Balzarini J (2004) TSAO compounds: the comprehensive story of a unique family of HIV-1-specific inhibitors of reverse transcriptase. Curr Top Med Chem 4:945-963.
13. Ceccherini-Silberstein F, Gago F, Santoro M, Gori C, Svicher V, Rodríguez-Barrios F, D'Arrigo R, Ciccozzi M, Bertoli A, d'Arminio Monforte A, et al. (2005) High sequence conservation of HIV-1 reverse transcriptase under drug pressure despite a continuous appearance of mutations. J Virology, in press.
14. D'Aquila RT and Summers WC (1989) HIV-1 reverse transcriptase/ ribonuclease H: high level expression in Escherichia coli from a plasmid constructed using the polymerase chain reaction. J Acquir Immune Defic Syndr 2:579-587.
15. De Clercq E (2000) Reverse transcriptase inhibitors as anti-HIV drugs, in Antivirals against AIDS (Unger RE, Kreuter J, and Rübsamen-Waigmann H eds) pp 107-150, Marcel Dekker, Inc., New York.
16. De Clercq E (2002) Strategies in the design of antiviral drugs. Nat Rev Drug Discov 1:13-25.
17. Ding J, Das K, Moereels H, Koymans L, Andries K, Janssen PA, Hughes SH, and Arnold E (1995) Structure of HIV-1 RT/TIBO R86183 complex reveals similarity in the binding of diverse nonnucleoside inhibitors. Nat Struct Biol 2:407-415.
18. Esnouf R, Ren J, Ross C, Jones Y, Stammers D, and Stuart D (1995) Mechanism of inhibition of HIV-1 reverse transcriptase by non-nucleoside inhibitors. Nat Struct Biol 2:303-308.
19. Goel R, Beard WA, Kumar A, Casas-Finet JR, Strub M-P, Stahl SJ, Lewis MS, Bebenek K, Becerra S, Kunkel TA, et al. (1993) Structure/function studies of HIV-1 reverse transcriptase: dimerization-defective mutant L289K. Biochemistry 32: 13012-13018.
20. Harris D, Lee R, Misra HS, Pandey PK, and Pandey VN (1998) The p51 subunit of human immunodeficiency virus type 1 reverse transcriptase is essential in loading the p66 subunit on the template primer. Biochemistry 37:5903-5908.
21. Hopkins AL, Ren J, Esnouf RM, Willcox BE, Jones EY, Ross C, Miyasaka T, Walker RT, Tanaka H, Stammers DK, et al. (1996) Complexes of HIV-1 reverse transcriptase with inhibitors of the HEPT series reveal conformational changes relevant to the design of potent non-nucleoside inhibitors. J Med Chem 39:1589-1600.
22. Jonckheere H, Taymans JM, Balzarini J, Velázquez S, Camarasa M-J, Desmyter J, De Clercq E, and Annë J (1994) Resistance of HIV-1 reverse transcriptase against [2′,5′-bis-O-(tert-butyldimethylsilyl)- 3′-spiro-5″-(4″-amino-1″,2″-oxathiole-2″, 2″-dioxide) (TSAO) derivatives is determined by the mutation Glu138→Lys on the p51 subunit. J Biol Chem 269:25255-25258.
23. Kohlstaedt LA, Wang J, Friedman JM, Rice PA, and Steitz TA (1992) Crystal structure of 3.5 Å resolution of HIV-1 reverse transcriptase complexed with an inhibitor. Science (Wash DC) 256:1783-1790.
24. Menéndez-Arias L, Abraha A, Quinones-Mateu ME, Mas A, Camarasa M-J, and Arts EJ (2001) Functional characterization of chimeric reverse transcriptases with polypeptide subunits of highly divergent HIV-1 group M and O strains. J Biol Chem 276:27470-27479.
25. Pandey PK, Kaushik N, Singh K, Sharma B, Upadhyay AK, Kumar S, Harris D, and Pandey VN (2002) Insertion of a small peptide of six amino acids into the β7-β8 loop of the p51 subunit of HIV-1 reverse transcriptase perturbs the heterodimer and affects its activities. BMC Biochem 3:18-31.
26. Pandey PK, Kaushik N, Talele TT, Yadav PN, and Pandey VN (2001) The beta7-beta8 loop of the p51 subunit in the heterodimeric (p66/p51) human immunodeficiency virus type 1 reverse transcriptase is essential for the catalytic function of the p66 subunit. Biochemistry 40:9505-9512.
27. Pelemans H, Esnouf R, Jonckheere H, De Clercq E, and Balzarini J (1998) Mutational analysis of Tyr-318 within the non-nucleoside reverse transcriptase inhibitor binding pocket of human immunodeficiency virus type 2 reverse transcriptase. J Biol Chem 273:34234-34239.
28. Ren J, Esnouf R, Garman E, Somers D, Ross C, Kirby I, Keeling J, Darby G, Jones Y, Stuart D, et al. (1995) High resolution structures of HIV-1 RT from four RT-inhibitor complexes. Nat Struct Biol 2:293-302.
29. Ren J, Milton J, Weaver KL, Short SA, Stuart DI, and Stammers DK (2000) Structural basis for the resilience of efavirenz (DMP-266) to drug resistance mutations in HIV-1 reverse transcriptase. Structure Fold Des 8:1089-1094.
30. Restle T, Muller B, and Goody RS (1990) Dimerization of human immunodeficiency virus type 1 reverse transcriptase. A target for chemotherapeutic intervention. J Biol Chem 265:8986-8988.
31. Rodriguez-Barrios F, Pérez C, San-Félix A, Camarasa M-J, Pelemans H, Balzarini J, and Gago F (2001) Identification of a putative binding site for TSAO-T derivatives at the p51/p66 interface of HIV-1 reverse transcriptase. J Med Chem 44:1853-1865.
32. Schinazi RF, Larder BA, and Mellors JW (2001) Mutations in retroviral genes associated with drug resistance: 2000-2001 update. Int Antiviral News 8:65-91.
33. Sluis-Cremer N, Arion D, and Parniak MA (2002) Destabilization of the HIV-1 reverse transcriptase dimer upon interaction with N-acyl hydrazone inhibitors. Mol Pharmacol 62:398-405.
34. Sluis-Cremer N, Dmitrienko GI, Balzarini J, Camarasa M-J, and Parniak MA (2000) Human immunodeficiency virus type 1 reverse transcriptase dimer destabilization by 1-[spiro[4″-amino-2″,2″-dioxo-1″, 2″-oxathiole-5″,3′-[2′,5′-bis-O-(tert- butyldimethylsilyl)-β-D-ribofuranosyl]]]-3-ethylthymine. Biochemistry 39:1427-1433.
35. Tachedjian G, Aronson H-EG, de los Santos M, Seehra J, McCoy JM, and Goff SP (2003) Role of residues in the tryptophan repeat motif for HIV-1 reverse transcriptase dimerization. J Mol Biol 326:381-396.
36. Tachedjian G and Goff SP (2003) The effect of NNRTIs on HIV reverse transcriptase dimerization. Curr Opin Investig Drugs 4:966-973.
37. Tachedjian G, Orlova M, Sarafianos SG, Arnold E, and Goff SP (2001) Nonnucleoside reverse transcriptase inhibitors are chemical enhancers of dimerization of the HIV type 1 reverse transcriptase. Proc Natl Acad Sci USA 98:7188-7193.
38. Wang J, Smerdon SJ, Jager J, Kohlstaedt LA, Rice PA, Friedman JM, and Steitz TA (1994) Structural basis of asymmetry in the human immunodeficiency virus type 1 reverse transcriptase heterodimer. Proc Natl Acad Sci USA 91:7242-7246.